Lifecore Biomedical Inc. (LFCR) shares jumped 54.29% during regular trading on Monday after the company announced it will be acquired by private equity firm Webster Equity Partners. The deal values the contract drug manufacturer at approximately $6.50 per share, a substantial premium to LFCR's prior closing price of $4.20.
What happened
Lifecore Biomedical disclosed the acquisition agreement via an 8-K filing with the Securities and Exchange Commission on September 28, 2026. The company announced it has entered into a definitive agreement to be acquired by Webster Equity Partners, a healthcare-focused private equity firm. GlobeNewsWire published the announcement at 12:45 p.m. ET on the same day. Trading volume surged to more than 3 million shares, compared with the stock's average daily volume of approximately 167,000 shares.
Why the stock moved
The 54% gain reflects investor optimism about the acquisition premium. At approximately $6.50 per share, the deal offers LFCR shareholders a meaningful uplift from the pre-announcement price of $4.20. The acquisition provides shareholders with immediate liquidity at a premium, while positioning Lifecore Biomedical under the ownership of a firm specializing in healthcare services investments. The 8-K filing formalized the transaction terms that drove the immediate price reaction. For the latest quote, filings, and news on LFCR, visit Lifecore Biomedical on Vantafin.
The numbers
Lifecore Biomedical opened at $6.52 and reached a session high of $6.48. The company has a market capitalization of approximately $243 million with 37.5 million shares outstanding. Average daily volume over the past several months was roughly 167,000 shares, making Monday's volume of 3 million shares approximately 18 times the typical daily turnover. Short interest stands at 2.67 million shares, with days to cover of nearly 16 based on recent trading activity.
What to watch
Investors should monitor for the completion of the acquisition process, including regulatory approvals and any shareholder vote requirements. The deal terms, including the exact per-share consideration and timeline to closing, will be detailed in the proxy statement that Lifecore is expected to file. Any changes to the agreed-upon price or termination of negotiations could significantly impact LFCR's valuation. Additionally, traders with short positions may face elevated borrowing costs given the sharp move and increased volatility in the stock.